Metabolic syndrome in stable long-term antipsychotic monotherapy and polypharmacy among patients with schizophrenia: a real-world comparative study
BackgroundMetabolic syndrome is a major contributor to premature cardiovascular morbidity and mortality among people with schizophrenia. Antipsychotic polypharmacy is common, but its independent metabolic burden remains uncertain.ObjectiveTo compare metabolic syndrome in patients receiving stable long-term antipsychotic monotherapy or polypharmacy and to examine high metabolic-risk exposure,…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
Belonging Begins in the Body
United States
-
Sex differences in sleep architecture among patients with severe mental disorders: a polysomnographic study
Switzerland
-
Comparative efficacy of naltrexone-accelerated versus sublingual buprenorphine in opioid withdrawal management and initiating injectable naltrexone treatment: study protocol for a randomized controlled trial
Switzerland
-
A comparison of recovery benefits associated with participation in SMART Recovery, AA, both SMART and AA, or neither, following a new alcohol use disorder recovery attempt
Switzerland
-
Personality and cognition across the lifespan: investigating their interplay and age-related differences
Switzerland
-
Clinical and resting-state EEG changes following neurofeedback in adult refugees with persistent trauma-related symptoms: a transdiagnostic pre–post observational study
Switzerland
-
Disability and its correlates among older adults with common mental disorders in China: a 5-year follow-up study
Switzerland
-
Referrals for suicidality to a UK child and adolescent mental health service: an evaluation of the policy and practice context of response to suicidal young people
Switzerland